By Assoc. Prof. Dr. Mehmet Sorar | Published: 05.02.2025
When Medications Fail: DBS and Botulinum Toxin for Dystonia
When medicines do not control dystonia, the two main options are botulinum toxin injections and deep brain stimulation (DBS). Neither removes the condition, because no cure is known, but both can ease symptoms. Botulinum toxin has moderate-certainty trial evidence in cervical (neck) dystonia. DBS evidence comes mostly from uncontrolled series in isolated dystonia, which occurs without other neurological signs, and the NHS offers DBS when other treatments fail.
What is known about medicines for dystonia?
Medicines are named, but published figures are scarce. The NHS lists muscle-relaxing medicines, and a 2018 review in Nature Reviews Disease Primers counts anticholinergic drugs, one class of oral medicine, among effective symptomatic treatments. Neither gives figures for benefit or side effects, and neither defines when a medicine counts as having failed, so that judgement is made with your doctor. The choice and the dose belong to the treating doctor, and a medicine should not be stopped on your own.
How much does botulinum toxin help, and what are its limits?
In cervical dystonia, botulinum toxin gives a measurable benefit over placebo, with moderate certainty of evidence. A 2020 Cochrane review pooled 9 double-blind, placebo-controlled trials with 1,144 adults. At week 4 the total score on the Toronto Western Spasmodic Torticollis Rating Scale, a rating scale for neck dystonia, fell by a mean of 8.09 points more with the toxin than with placebo (95% confidence interval 6.22 to 9.96), about an 18.4% improvement from baseline. The pain subscore fell by 2.11 points more.
The review also set out the limits of these results:
- Seven of the nine trials excluded people who had responded poorly to the toxin, so the groups were enriched for responders.
- Only one trial was independently funded, and each assessed a single treatment session.
- The review found no randomized evidence on repeated cycles, the optimal interval, how long the effect lasts, quality of life or guidance by electromyography (EMG, a recording of muscle activity), and no clear link between dose and response.
- Side effects were more frequent with the toxin (1.23 times as often as with placebo). The most common were neck weakness (14%), trouble swallowing (11%) and general weakness or tiredness (8%).
The NHS says the injections go into the affected muscles about every 3 months. The Cochrane review covers the neck only, so its figures do not apply to other areas such as the eyelids or voice box. Ask your doctor what is known for the area affected in your case.
How much does deep brain stimulation help?
In isolated dystonia, pooled results are large, but they rest mostly on uncontrolled series. A 2017 meta-analysis in the European Journal of Neurology combined 24 studies of 523 people with isolated inherited or idiopathic (no known cause) dystonia who had stimulation of the globus pallidus (GPi) on both sides. At the last follow-up, after about 32.5 months on average, the Burke-Fahn-Marsden motor score had improved by a pooled 65.2% (95% confidence interval 59.6% to 70.7%) and the disability score by 58.6%. Outcomes were better in people with higher (worse) scores before surgery and in those who were younger at surgery.
That figure applies to selected people with isolated dystonia and should not be applied to every type. A 2021 review in Frontiers in Human Neuroscience covered 35 studies, with 319 patients stimulated in the GPi and 113 in the subthalamic nucleus (STN), and an average follow-up of 12.5 months. The two targets were equivalent for effect, quality of life, mood and the frequency of adverse events. Isolated dystonia responded better than secondary non-hereditary dystonia, which also had more adverse events. Focal dystonia gained more in disability scores than segmental or generalised forms. Follow-up was short and most studies were not randomized.
What is known about the risks of DBS in dystonia?
No reliable complication rate specific to dystonia is available. The 2017 meta-analysis could not pool safety data because they were reported inconsistently. The 2021 review judged both targets safe and found them equal on adverse events, but it gave no rates.
One indirect figure comes from a study of DBS across several conditions. This retrospective chart review from one centre, whose authors include Assoc. Prof. Mehmet Sorar, covered 181 patients with 359 leads (stimulating wires) implanted over six years. It was published in the journal Parkinson's Disease. Of these patients, 159 had Parkinson's disease, 13 dystonia and 9 essential tremor. Early complications were confusion in 6.6%, bleeding inside the brain in 2.2%, stroke in 1.1% and seizures in 1.1%. The mean follow-up was 3.4 years. These figures come from a group made up mostly of Parkinson's patients and are not specific to dystonia.
How do the two options compare?
The two have not been measured the same way, so the numbers cannot be set against each other. The 18.4% and 65.2% come from different scales, different time points and different study designs.
| Feature | Botulinum toxin | DBS |
|---|---|---|
| Type of evidence | 9 placebo-controlled trials, cervical dystonia, 1,144 adults | 24 studies, mostly uncontrolled series, 523 patients, isolated dystonia |
| Measured at | Week 4, single session | About 32.5 months (2017) and 12.5 months (2021) |
| Repeat needed | The effect wears off; about every 3 months (NHS) | Long-term device checks and battery care, set out by the implanting centre |
| Known side effects | Neck weakness 14%, swallowing trouble 11%, general weakness 8% | No rate specific to dystonia |
| When it comes in | By type of dystonia, injected into muscles | NHS: if other treatments fail |
Which side effects need urgent help?
If you cannot swallow food or liquid after an injection, or you have difficulty breathing, call your local emergency number (112 in Türkiye) without waiting. Milder trouble swallowing, neck weakness, or widespread weakness and tiredness should be reported to the team the same day, since these were the most common treatment-related events.
After DBS surgery, treat sudden weakness, trouble speaking, a severe headache, confusion or a seizure as an emergency and call the same number, because bleeding, stroke and seizures were reported in the study above. Fever, or redness, swelling or discharge at a wound, should reach the surgical centre the same day.
If medicines and toxin are not helping enough, or side effects are hard to bear, ask whether DBS should be assessed, which is the route the NHS describes.
For the wider picture, see What is dystonia? and The reality of dystonia and paths to relief. Follow-up after treatment is covered in Living with dystonia after treatment, and how a DBS system works in What is deep brain stimulation?.
Sources
- NHS: Dystonia
- Nature Reviews Disease Primers: Dystonia (2018)
- Cochrane: Botulinum toxin type A therapy for cervical dystonia (2020)
- European Journal of Neurology: Efficacy of pallidal stimulation in isolated dystonia, a systematic review and meta-analysis (2017)
- Frontiers in Human Neuroscience: Deep Brain Stimulation Treating Dystonia, a systematic review (2021)
- Parkinson's Disease: Surgical and hardware-related complications of deep brain stimulation surgery, single-center study of 181 patients (2018)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: Distoni